Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iofolastat I-123
- Development stage
- Phase 1
- Lead developer
- Lantheus
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Iofolastat I-123 is a radiopharmaceutical small molecule, specifically a radiolabeled glutamate–urea–lysine analogue, designed for molecular imaging of prostate cancer. It selectively binds to the prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein highly expressed on malignant prostate epithelial cells and the neovasculature of various solid tumors. Upon binding PSMA, iofolastat I-123 enables visualization of PSMA-expressing cells using gamma scintigraphy or SPECT imaging due to its iodine‑123 radioisotope label. The drug was developed by Molecular Insight Pharmaceuticals for diagnostic use in detecting metastatic prostate cancer lesions in bone and soft tissue[1][3][4][7].
- Brand names
- Trofex
- Other names
- iofolastat (123I)IOFOLASTAT I 123iofolastat I123
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on Iofolastat I-123.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iofolastat I-123.